Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX Hexa in Healthy Infants

Trial Profile

Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX Hexa in Healthy Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs Rotavirus W179-9 vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Mar 2009 Results published in The Pediatric Infectious Disease Journal.
    • 18 Feb 2009 Actual patient number changed from 522 to 403 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Actual study completion date (June 2007 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top